CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia
Summary
The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.
What changed
The USPTO published a patent application covering CD19/CD22 CAR T-cell products and associated treatment methods for CD19+ or CD22+ haematological malignancies, with particular focus on high-risk or relapsed pediatric acute lymphoblastic leukemia. The application includes CPC classifications related to therapeutic compositions and methods.
For biotechnology and pharmaceutical companies developing CAR T-cell or related cell therapy products, this published application represents prior art that may affect freedom to operate assessments. Competitors should evaluate whether their development programs may overlap with the claimed subject matter to identify potential licensing needs or design-around opportunities.
What to do next
- Monitor patent prosecution status
- Assess freedom to operate for CAR T-cell development programs
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CD19/C22 CAR T-CELL TREATMENT OF HIGH RISK OR RELAPSED PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
Application US20260097122A1 Kind: A1 Apr 09, 2026
Inventors
Martin Pulé, Persis Amrolia, Sara Ghorashian
Abstract
The present disclosure relates to CD19/22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.
CPC Classifications
A61K 40/4211 A61K 40/11 A61K 40/31 A61K 40/4212 A61P 35/02 A61K 2239/13 A61K 2239/28 A61K 2239/48
Filing Date
2023-05-10
Application No.
18862269
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.